KCM
SXTP icon

Kathmere Capital Management’s 60 Degrees Pharmaceuticals SXTP Stock Holding History

Kathmere Capital Management’s Portfolio SXTP Stock Details SXTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$253K Buy
+144,683
New +$411K 0.02% 515

Other funds holding SXTP

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TPWA
Twin Peaks Wealth Advisors Burlingame, California $397M AUM 23.23% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Kathmere Capital Management's SXTP Position: Q1 2026 in Review

Kathmere Capital Management opened a new position in 60 Degrees Pharmaceuticals (SXTP) in Q1 2026: 144,683 shares worth $253K. The stake represents 0.02% of the portfolio and ranks #515 among its holdings.

8 funds tracked by Wall St. Rank hold SXTP as of Q1 2026.

  • Kathmere Capital Management held 144,683 shares of 60 Degrees Pharmaceuticals worth $253K as of Q1 2026.
  • 60 Degrees Pharmaceuticals was a new Kathmere Capital Management position in Q1 2026.
  • 60 Degrees Pharmaceuticals made up 0.02% of Kathmere Capital Management's portfolio in Q1 2026, its #515 holding.
  • 8 funds tracked by Wall St. Rank held 60 Degrees Pharmaceuticals as of Q1 2026.

Based on Kathmere Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.